Research & KnowledgeEvent: September 2, 2026
Nexus BioQuest investigated whether immune complex-driven NETosis could be therapeutically modulated using freshly isolated human neutrophils.
Published
Signal category
Research & Knowledge
Quote
“At Nexus BioQuest, we investigated whether immune complex-driven NETosis could be therapeutically modulated.”
— Nexus BioQuest team
Company
Nexus BioQuest
Driving innovative solutions in preclinical immunology
- Industry
- Research Services
- Location
- Bristol, GB
- Company size
- 38 employees
Driving innovative solutions in preclinical immunology
Founded 2022